Coherus Oncology, Inc. CHRS
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 61.00% | -- | -- | -- | -82.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 61.00% | -- | -- | -- | -82.30% |
| Cost of Revenue | 37.22% | -- | -- | -- | -90.44% |
| Gross Profit | 74.63% | -- | -- | -- | -65.43% |
| SG&A Expenses | -19.95% | -- | -- | -- | -26.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.59% | -- | -- | -- | -41.68% |
| Operating Income | 15.92% | -- | -- | -- | 3.41% |
| Income Before Tax | 13.34% | -- | -- | -- | 23.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.34% | -- | -- | -- | 23.22% |
| Earnings from Discontinued Operations | -92.07% | -- | -- | -- | 71.82% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -173.51% | -- | -- | -- | 712.65% |
| EBIT | 15.92% | -- | -- | -- | 3.41% |
| EBITDA | 15.76% | -- | -- | -- | 3.49% |
| EPS Basic | -166.87% | -- | -- | -- | 582.47% |
| Normalized Basic EPS | 24.49% | -- | -- | -- | 16.46% |
| EPS Diluted | -166.87% | -- | -- | -- | 568.57% |
| Normalized Diluted EPS | 24.49% | -- | -- | -- | 16.46% |
| Average Basic Shares Outstanding | 14.11% | -- | -- | -- | 5.90% |
| Average Diluted Shares Outstanding | 14.11% | -- | -- | -- | 5.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |